 Paula Araya
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 11 | 2025 | 504 | 2.000 |
Why?
| | Motor Skills Disorders | 1 | 2025 | 29 | 0.880 |
Why?
| | Motor Skills | 1 | 2025 | 105 | 0.830 |
Why?
| | Autistic Disorder | 1 | 2025 | 211 | 0.730 |
Why?
| | Child Development | 1 | 2025 | 496 | 0.620 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 413 | 0.520 |
Why?
| | Autoimmunity | 3 | 2024 | 908 | 0.480 |
Why?
| | Proteome | 4 | 2025 | 483 | 0.340 |
Why?
| | Transcriptome | 5 | 2025 | 1007 | 0.330 |
Why?
| | Interferon-alpha | 3 | 2020 | 195 | 0.320 |
Why?
| | Melanoma, Experimental | 3 | 2019 | 110 | 0.300 |
Why?
| | Interferons | 4 | 2023 | 194 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 211 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 911 | 0.260 |
Why?
| | Dendritic Cells | 2 | 2019 | 487 | 0.240 |
Why?
| | Human Development | 1 | 2025 | 22 | 0.230 |
Why?
| | New Zealand | 1 | 2025 | 55 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 153 | 0.220 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 27 | 0.220 |
Why?
| | Erythropoiesis | 1 | 2024 | 56 | 0.210 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2024 | 42 | 0.210 |
Why?
| | Heme | 1 | 2024 | 75 | 0.210 |
Why?
| | Piperidines | 1 | 2024 | 217 | 0.200 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 94 | 0.190 |
Why?
| | Growth Disorders | 1 | 2022 | 87 | 0.190 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2022 | 68 | 0.180 |
Why?
| | Metabolome | 2 | 2025 | 366 | 0.180 |
Why?
| | Toll-Like Receptor 3 | 2 | 2019 | 28 | 0.180 |
Why?
| | Developmental Disabilities | 1 | 2025 | 288 | 0.180 |
Why?
| | Blood | 1 | 2022 | 110 | 0.180 |
Why?
| | Child, Preschool | 6 | 2025 | 11511 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2023 | 3577 | 0.170 |
Why?
| | Pyrimidines | 1 | 2024 | 510 | 0.170 |
Why?
| | Seroconversion | 1 | 2021 | 44 | 0.170 |
Why?
| | Janus Kinase 1 | 1 | 2020 | 26 | 0.170 |
Why?
| | Janus Kinase 2 | 1 | 2020 | 32 | 0.170 |
Why?
| | Interferon Regulatory Factors | 1 | 2021 | 45 | 0.170 |
Why?
| | Azetidines | 1 | 2020 | 46 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 314 | 0.160 |
Why?
| | Poly A-U | 2 | 2019 | 4 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2021 | 244 | 0.160 |
Why?
| | Sex Characteristics | 1 | 2025 | 783 | 0.160 |
Why?
| | Biomarkers | 4 | 2025 | 4180 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 393 | 0.160 |
Why?
| | Photochemotherapy | 1 | 2019 | 39 | 0.150 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1761 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2025 | 600 | 0.150 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 22 | 0.150 |
Why?
| | Interferon Type I | 1 | 2019 | 140 | 0.150 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 412 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 174 | 0.140 |
Why?
| | Cell Lineage | 1 | 2019 | 352 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 257 | 0.130 |
Why?
| | Signal Transduction | 4 | 2024 | 5116 | 0.130 |
Why?
| | Cellular Senescence | 1 | 2019 | 218 | 0.130 |
Why?
| | Humans | 18 | 2025 | 141284 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2929 | 0.130 |
Why?
| | Hypoxia | 1 | 2024 | 1163 | 0.130 |
Why?
| | Neurons | 1 | 2025 | 1611 | 0.130 |
Why?
| | Female | 12 | 2025 | 75814 | 0.130 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2017 | 105 | 0.120 |
Why?
| | Infant | 3 | 2025 | 9820 | 0.120 |
Why?
| | Sulfonamides | 1 | 2020 | 576 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 784 | 0.120 |
Why?
| | Antigens, CD | 1 | 2019 | 537 | 0.120 |
Why?
| | Male | 10 | 2025 | 70140 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1136 | 0.120 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 295 | 0.120 |
Why?
| | Interferon-beta | 1 | 2016 | 93 | 0.120 |
Why?
| | Young Adult | 5 | 2025 | 13727 | 0.110 |
Why?
| | Adult | 9 | 2025 | 39319 | 0.110 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 880 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1919 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 636 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 918 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 711 | 0.110 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 62 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2019 | 1983 | 0.090 |
Why?
| | Datasets as Topic | 2 | 2022 | 124 | 0.090 |
Why?
| | Immunotherapy | 1 | 2016 | 641 | 0.090 |
Why?
| | Adolescent | 6 | 2025 | 22116 | 0.080 |
Why?
| | Animals | 9 | 2025 | 37328 | 0.080 |
Why?
| | Child | 6 | 2025 | 22390 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2529 | 0.070 |
Why?
| | Mice | 6 | 2024 | 17969 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2246 | 0.070 |
Why?
| | Proteomics | 2 | 2023 | 1137 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 60 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 112 | 0.060 |
Why?
| | Middle Aged | 5 | 2025 | 34658 | 0.050 |
Why?
| | Apoptosis | 2 | 2025 | 2487 | 0.050 |
Why?
| | Cell Death | 1 | 2025 | 386 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4414 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 5866 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 207 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 26 | 0.050 |
Why?
| | Erythropoietin | 1 | 2024 | 98 | 0.050 |
Why?
| | L-Selectin | 1 | 2023 | 24 | 0.050 |
Why?
| | Receptors, Interferon | 1 | 2023 | 52 | 0.050 |
Why?
| | Perforin | 1 | 2023 | 19 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 48 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2021 | 3502 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 30 | 0.040 |
Why?
| | Access to Information | 1 | 2021 | 45 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2024 | 449 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2019 | 3042 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 170 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 115 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2019 | 16 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 193 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 187 | 0.040 |
Why?
| | Purines | 1 | 2020 | 182 | 0.040 |
Why?
| | Photosensitizing Agents | 1 | 2019 | 42 | 0.040 |
Why?
| | Biomedical Research | 1 | 2025 | 684 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 407 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2021 | 308 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 513 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1466 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5556 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 632 | 0.030 |
Why?
| | Pyrazoles | 1 | 2020 | 482 | 0.030 |
Why?
| | Light | 1 | 2019 | 396 | 0.030 |
Why?
| | Cytokines | 1 | 2024 | 2079 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 1111 | 0.030 |
Why?
| | Gene Silencing | 1 | 2017 | 198 | 0.030 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2016 | 17 | 0.030 |
Why?
| | CD11c Antigen | 1 | 2016 | 40 | 0.030 |
Why?
| | Immunologic Surveillance | 1 | 2016 | 26 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1671 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 702 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1182 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 251 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 153 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3172 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 847 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 218 | 0.030 |
Why?
| | Mice, Nude | 1 | 2016 | 700 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 391 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1250 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2165 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 857 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1810 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7948 | 0.020 |
Why?
| | Disease Progression | 1 | 2021 | 2808 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 1261 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3024 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4080 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1821 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2264 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2502 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 11216 | 0.020 |
Why?
| | Aged | 1 | 2025 | 24836 | 0.010 |
Why?
|
|
Araya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|